The impact of pemafibrate on hypertriglyceridemia in patients with type 2 diabetes: A prospective cohort study
Latest Information Update: 14 Nov 2022
At a glance
- Drugs Pemafibrate (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia
- Focus Therapeutic Use
- Acronyms PARM-T2D
Most Recent Events
- 01 Oct 2022 Primary endpoint has been met, (Changes of TG and HDL-C before and after administration of pemafibrate), as per Results published in the Diabetes Research and Clinical Practice
- 01 Oct 2022 Results published in the Diabetes Research and Clinical Practice
- 02 Aug 2022 Status changed from recruiting to completed.